| Marjorie C. Green |
Marjorie C. Green currently works at NeoGenomics, Inc., as Independent Director from 2025 and Merck & Co., Inc., as SVP, Head-Oncology & Global Clinical Development. Dr. Green received her undergraduate degree from the University of Notre Dame and doctorate degree from the University of Texas Medical Branch. |
| Chirfi Guindo |
Chirfi Guindo currently works at Beam Therapeutics, Inc., as Independent Director from 2024 and Merck & Co., Inc., as Chief Marketing Officer. Mr. Guindo also formerly worked at Merck Canada, Inc., as President & Managing Director from 2014 to 2017 and Biogen, Inc., as EVP-Global Product Strategy & Commercialization from 2018 to 2022. Mr. Guindo received his undergraduate degree from École Centrale Paris and Masters Business Admin degree from The Leonard N Stern School of Business. |
| Caroline A. Litchfield |
Ms. Caroline A. Litchfield is an Independent Director at Verizon Communications, Inc., a Chief Financial Officer & Director at Immune Design Corp. and a Chief Financial Officer & Executive Vice President at Merck & Co., Inc. She is on the Board of Directors at Verizon Communications, Inc. and Immune Design Corp. Ms. Litchfield was previously employed as a Finance Director by Merck Sharp & Dohme Ltd. She also served on the board at Fulford (India) Ltd. and Organon & Co. She received her undergraduate degree from the University of Leicester. |
| Dave Williams |
Dave Williams is the founder of Merck Animal Health Ventures. Current jobs include Director at the National Center for Women & Information Technology and Executive VP, Chief Information & Digital Officer at Merck & Co., Inc. Former job includes Chief Information Officer at Merck Animal Health. Education includes an undergraduate degree from the University of Scranton. |
| Betty D. Larson |
Betty D. Larson currently works at Baxter Credit Union, as Director, BD Foundation, Inc., as President & Secretary, and Merck & Co., Inc., as Chief Human Resources Officer & Executive VP from 2024. Ms. Larson also formerly worked at United Way of Lake County, as Director, Summit Speech School, as Director, Overlook Foundation (United States), as Director, Fortrea Holdings, Inc., as Independent Director from 2023 to 2024, C. R. Bard, Inc. (New Jersey), as Vice President-Human Resources from 2014 to 2017, Baxter Healthcare Corp., as Senior Vice President-Human Resources from 1999 to 2014, Becton, Dickinson & Co., as Executive Vice President-Human Resources from 2017 to 2018, and GE Healthcare Technologies, Inc., as Chief People Officer from 2023 to 2024. Ms. Larson received her undergraduate degree and graduate degree from the University of Illinois and Masters Business Admin degree from Kellogg School of Management. |
| Robert M. Davis |
Robert M. Davis currently works at Merck & Co., Inc., as Chairman, President & Chief Executive Officer, MSD Pharma (Singapore) Pte Ltd., as President, Chief Executive Officer & Director from 2021, Duke Energy Corp., as Independent Director from 2018, Project HOPE-The-People-To-People HealthFoundation, Inc., as Director, and AdvaMedDx, as Director. Mr. Davis also formerly worked at Gambro AB, as Chairman, C. R. Bard, Inc. (New Jersey), as Director from 2015 to 2017, Eli Lilly & Co., as Director-Corporate Financial Planning from 2002 to 2004, Baxter Healthcare Corp., as Chief Financial Officer & Vice President from 2006 to 2010, Baxter International, Inc., as VP & President-Medical Products Business from 2010 to 2014, and Rush University Medical Center, as Trustee. Mr. Davis received his undergraduate degree from Miami University, Masters Business Admin degree from Kellogg School of Management, and graduate degree from Northwestern University School of Law. |
| Jannie Oosthuizen |
Jannie Oosthuizen currently works at Merck & Co., Inc., as President-Merck Human Health from 2021, Merck Human Health US, as President from 2022, and Esor Ltd., as Manager-Legal & Human Resources. Mr. Oosthuizen received his graduate degree from North-West University. |
| Joseph Romanelli |
Mr. Joseph Romanelli is an Independent Director at Kimberly-Clark Corp. and a President-Human Health International at Merck & Co., Inc. He is on the Board of Directors at Kimberly-Clark Corp. Mr. Romanelli was previously employed as a Chief Executive Officer by Jixing Pharmaceutical Technology (Shanghai) Co., Ltd., a Head-Investor Relations by Merck & Co., Inc., and a Head-Investor Relations by Schering-Plough Corp. He received his undergraduate degree from the University of Delaware and an MBA from Gabelli School of Business. |
| Risa J. Lavizzo-Mourey |
Risa J. Lavizzo-Mourey currently works at Smithsonian Institution, as Chairman-Regents Board from 2014, Merck & Co., Inc., as Independent Director from 2020, Princeton Medical Center, as Director, and various other companies. Dr. Lavizzo-Mourey also formerly worked at The Robert Wood Johnson Foundation, as President Emerita & CEO, White House Health Care & Rehabilitation Center, Inc., as Co-Chairman from 1985 to 1998, Hess Corp., as Independent Director from 2004 to 2020, and various other companies. Dr. Lavizzo-Mourey received her undergraduate degree from Stony Brook University, doctorate degree in 1979 from Harvard Medical School, and Masters Business Admin degree in 1986 from The Wharton School of the University of Pennsylvania. |
| Inge G. Thulin |
Inge G. Thulin currently works at United States Council for International Business, as Vice Chairman from 2011, The Kennedy Center Corporate Fund, as Vice Chairman, Merck & Co., Inc., as Independent Director from 2018, The Council for the United States & Italy, as Director, Merck Sharp & Dohme Corp., as Director from 2018, Patricia Industries AB, as Director from 2019, MSD Pharma (Singapore) Pte Ltd., as Director from 2018, Council on Foreign Relations, Inc., as Member from 2013, The Business Roundtable, as Member from 2013, The Business Council, as Member, The World Economic Forum USA, Inc., as Member, The International Business Council, as Member, and Sällskapet, as Member from 2014. Mr. Thulin also formerly worked at 3M Co., as Executive Chairman from 2018 to 2019, Chevron Corp., as Independent Director from 2015 to 2020, Chevron Corp., as Director, The Toro Co., as Independent Director from 2007 to 2012, 3M Russia ZAO, as Managing Director, Forum Mondial de L'Economie, as Member, 3M Svenska AB, as Manager-Life Sciences Sector, and 3M Europe NV, as Manager-European Business Unit. Mr. Thulin received his undergraduate degree from the University of Gothenburg. |
| Thomas Henry Glocer |
Thomas Henry Glocer founded Angelic Ventures LP in 2012, where he is working as Founding Partner from 2012, Communitas Capital Partners LLC in 2017, where he is working as Partner from 2017, BlueVoyant LLC in 2017, where he is working as Executive Chairman from 2017, and various other companies. Mr. Glocer also currently works at Blueteam Investor LLC, as Chief Executive Officer, Merck & Co., Inc., as Lead Independent Director from 2021, Morgan Stanley, as Lead Independent Director from 2017, and various other companies. Mr. Glocer also formerly worked at Reuters Group Plc, as Chief Executive Officer & Director from 2001 to 2008, Thomson Reuters Plc, as Chief Executive Officer from 2001 to 2009, Thomson Reuters Corp., as Chief Executive Officer & Director from 2008 to 2011, and various other companies. Mr. Glocer received his undergraduate degree in 1981 from The Trustees of Columbia University in The City of New York and graduate degree in 1984 from Yale University. |
| Patricia Fiorello Russo |
Patricia Fiorello Russo currently works at Hewlett Packard Enterprise Co., as Independent Chairman from 2015, Merck & Co., Inc., as Independent Director from 1995, KKR Management LLC, as Independent Director from 2011, General Motors Co., as Lead Independent Director from 2021, KKR Group Co., Inc., as Independent Director from 2011, Merck Sharp & Dohme Corp., as Director from 1995, Arconic Defense, Inc., as Director, MSD Pharma (Singapore) Pte Ltd., as Director from 1995, KKR & Co., Inc., as Independent Director from 2011, The Conference Board, Inc., as Member, The Economic Club of New York, as Member, and The Business Council, as Member. Ms. Russo also formerly worked at Lucent Technologies, Inc., as Chairman & Chief Executive Officer from 2003 to 2006, Nokia of America Corp., as Chief Executive Officer & Director in 2008, Alcatel Lucent SA, as Chief Executive Officer from 2006 to 2008, Avaya LLC, as Chairman in 2002, Partnership for Drug-Free Kids, as Chairman, Arconic, Inc., as Lead Independent Director from 2015 to 2016, HP, Inc., as Lead Independent Director from 2014 to 2015, Schering-Plough Corp., as Director from 1995 to 2009, Motors Liquidation Co., as Lead Director, Alcoa Corp., as Director, DXC Technology Co., as Director, Howmet Aerospace, Inc., as Lead Independent Director from 2017 to 2018, Eastman Kodak Co., as President & Chief Operating Officer in 2001, and Georgetown University, as Trustee. Ms. Russo received her undergraduate degree from Georgetown University. |
| Pamela J. Craig |
Pamela J. Craig currently works at The Committee of 200, as Vice Chairman from 2017, Corning, Inc., as Independent Director from 2021, Merck & Co., Inc., as Independent Director from 2015, Progressive Corp., as Independent Director from 2018, Smith College, as Director, Junior Achievement of New Jersey, Inc., as Director, Merck Sharp & Dohme Corp., as Director, Comprehensive Development, Inc., as Director from 2012, and MSD Pharma (Singapore) Pte Ltd., as Director from 2015. Ms. Craig also formerly worked at C200 Foundation, as Chairman, 3M Co., as Independent Director from 2019 to 2023, Walmart, Inc., as Independent Director from 2015 to 2017, Akamai Technologies, Inc., as Independent Director from 2011 to 2019, VMware LLC, as Independent Director from 2014 to 2015, Accenture Ltd., as Chief Financial Officer from 2001 to 2011, Accenture SCA, as Chief Financial Officer, Accenture Plc, as Chief Financial Officer from 2006 to 2013, Accenture LLP, as Chief Financial Officer from 2006 to 2013, and Avanade, Inc., as Chief Financial Officer from 2006 to 2009. Ms. Craig received her undergraduate degree from Smith College and Masters Business Admin degree from The Leonard N Stern School of Business. |
| Douglas M. Baker |
Douglas M. Baker currently works at ChampionX Holding, Inc., as Chairman, Merck & Co., Inc., as Independent Director from 2022, Target Corp., as Independent Director from 2021, Minnesota Orchestral Association, as Director, Minneapolis Saint Paul Regional Economic Development Partners, as Director, Parent Aware For School Readiness, as Director, College of the Holy Cross (Massachusetts), as Trustee, Mayo Clinic, as Trustee from 2020, Chief Executives For Corporate Purpose, Inc., as Member, National Restaurant Association Educational Foundation, as Trustee-Emeritus, and E2SG Partners LP, as Founding Partner from 2022. Mr. Baker also formerly worked at Ecolab, Inc., as Executive Chairman from 2020 to 2022, U.S. Bancorp, as Independent Director from 2011 to 2018, and Nalco Holding Co., as Director. Mr. Baker received his undergraduate degree from College of the Holy Cross (Massachusetts). |
| Paul B. Rothman |
Paul B. Rothman currently works at Laboratory Corp. of America Holdings, as Independent Director from 2023, Merck & Co., Inc., as Independent Director from 2015, Merck Sharp & Dohme Corp., as Director from 2015, King Faisal Specialist Hospital & Research Centre, as Director, MSD Pharma (Singapore) Pte Ltd., as Director from 2015, Center for Medical Interoperability, as Director from 2015, Labcorp Holdings, Inc., as Independent Director from 2024, The Johns Hopkins Hospital, Inc., as Ex-Officio Trustee, American Academy of Arts & Sciences, as Member, American Association for the Advancement of Science, as Member, National Academy of Medicine (United States), as Member, Association of American Physicians, as Member, American Society for Clinical Investigation, as Member, and Johns Hopkins Community Physicians, Inc., as Trustee. Dr. Rothman also formerly worked at Johns Hopkins Medicine, Inc., as Chief Executive Officer from 2012 to 2022, The Johns Hopkins Health System Corp., as Vice Chairman, Cancer Genetics, Inc., as Director in 2014, The Johns Hopkins University, as Vice President-Medicine from 2012 to 2022, and the University of Iowa Carver College of Medicine, as Dean from 2008 to 2012. Dr. Rothman received his undergraduate degree from Massachusetts Institute of Technology and doctorate degree from Yale University. |
| Mary Ellen Coe |
Mary Ellen Coe currently works at Merck & Co., Inc., as Independent Director from 2019, Merck Sharp & Dohme Corp., as Director, MSD Pharma (Singapore) Pte Ltd., as Director from 2019, Google LLC, as President-Global Customer Solutions from 2017, and YouTube, Inc., as Chief Business Officer from 2022. Ms. Coe also formerly worked at Whole Foods Market, Inc., as Independent Director from 2016 to 2017. Ms. Coe received her undergraduate degree from the University of Michigan. |
| Stephen L. Mayo |
Stephen L. Mayo is the founder of Xencor, Inc. (1997). Dr. Mayo is also the founder of Molecular Simulations, Inc.,Protabit LLC. Current jobs include Independent Director at Merck & Co., Inc. since 2021, Independent Director at Sarepta Therapeutics, Inc. since 2021, Director at MSD Pharma (Singapore) Pte Ltd. since 2021, Independent Director at Allogene Therapeutics, Inc. since 2022, and Professor at California Institute of Technology since 2020. Former jobs include Director at American Association for the Advancement of Science from 2010 to 2014 and Director at The National Science Foundation from 2013 to 2018. Education includes a doctorate from California Institute of Technology (1987) and an undergraduate degree from The Pennsylvania State University (1983). |
| Kathy J. Warden |
Kathy J. Warden currently works at Northrop Grumman Corp., as Chairman, President & Chief Executive Officer from 2019, Federal Reserve Bank of Richmond, as Chairman from 2019, Greater Washington Partnership, as Vice Chairman, Merck & Co., Inc., as Independent Director from 2020, Catalyst, Inc., as Director from 2019, Wolf Trap Foundation for the Performing Arts, as Director, Merck Sharp & Dohme Corp., as Director from 2020, MSD Pharma (Singapore) Pte Ltd., as Director from 2020, The Business Roundtable, as Member, and AFCEA International, as Member. Ms. Warden also formerly worked at Aerospace Industries Association, as Vice Chairman, General Electric Information Services, as Director-Global Services Operating Unit, GE Aerospace, as Senior Manager, Veridian Corp., as Senior Vice President, Northrop Grumman Information Technology, Inc., as President, Northrop Grumman Information Technology, Inc., as Vice President & GM-Cyber Intelligence Division, Northrop Grumman Mission Systems, as President, General Dynamics Advanced Information Systems, Inc., as Vice President-Intelligence Systems, and James Madison University, as Member-Visitors Board. Ms. Warden received her Masters Business Admin degree from George Washington University and undergraduate degree from James Madison University. |
| Christine E. Seidman |
Christine E. Seidman is the founder of MyoKardia, Inc. (2012). Dr. Seidman is currently an Independent Director at Merck & Co., Inc. (2020), Director-Cardiovascular Genetics Center at The Brigham & Women's Hospital, Inc. (1987), Director at The Burroughs Wellcome Fund, Director at Merck Sharp & Dohme Corp. (2020), Director at MSD Pharma (Singapore) Pte Ltd. (2020), Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the National Academy of Medicine (United States), Member of the American Society for Clinical Investigation, Professor at Harvard Medical School (1997), Member of the Association of University Cardiologists, Scientific Advisory Board at BridgeBio Pharma, Inc., and Venture Partner at Catalio Capital Management LP. Dr. Seidman obtained an undergraduate degree from Harvard University and a doctorate from George Washington University. |
